PEG-Loxenatide

聚乙二醇洛塞那肽

Report date: 2024/09/19 11:28:16
NME

Base Information

Drug NamePEG-Loxenatide
Drug Alias NamePolyethylene glycol loxenatidePEG loxenatide - Jiangsu Hengrui Medicine Co.Pegloxenatide孚来美PEX-168
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Endometrial Hyperplasia
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2019/05/05
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdFudan University
Inactive CompaniesJiangsu Hengrui Medicine Co Ltd
Active IndicationsObesityDiabetes Mellitus, Type 2Endometrial Hyperplasia
Inactive IndicationsN/A

Other Information

ATC CodeA10B
Related LinksN/A